Correspondence 0001628280-24-001123 from Innate Pharma SA (IPHA, IPHYF) (CIK 0001598599) (IPHA)
Innate Pharma SA (IPHA, IPHYF) (CIK 0001598599)
Date: Jan. 11, 2024 · CIK: 0001598599 · Accession: 0001628280-24-001123
AI Filing Summary & Sentiment
File numbers found in text: 333-276164
Letter
Document
Innate Pharma S.A.
17, avenue de Luminy-BP 30191
13009 Marseille, France
January 11, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Jimmy McNamara
RE: Innate Pharma S.A.
Registration Statement on Form F-3 (File No. 333-276164)
Acceleration Request
Requested Date: January 15, 2024
Requested Time: 4:30 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, Innate Pharma S.A. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 to become effective on January 15, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable. The Registrant also hereby requests a copy of the written order verifying the effective date.
Please contact Linda Hesse of Jones Day at +33 1 56 59 39 39 if you have any questions concerning the foregoing. Thank you for your attention to this matter.
Very truly yours,
INNATE PHARMA S.A.
Show Raw Text
CORRESP 1 filename1.htm Document Innate Pharma S.A. 17, avenue de Luminy-BP 30191 13009 Marseille, France January 11, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jimmy McNamara RE: Innate Pharma S.A. Registration Statement on Form F-3 (File No. 333-276164) Acceleration Request Requested Date: January 15, 2024 Requested Time: 4:30 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, Innate Pharma S.A. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 to become effective on January 15, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable. The Registrant also hereby requests a copy of the written order verifying the effective date. Please contact Linda Hesse of Jones Day at +33 1 56 59 39 39 if you have any questions concerning the foregoing. Thank you for your attention to this matter. Very truly yours, INNATE PHARMA S.A. By: /s/ Hervé Brailly Hervé Brailly Interim Chief Executive Officer cc: Linda Hesse, Jones Day